| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
IC50: 3 nM (rat PAC1), 2 nM (rat VPAC1), 5 nM (human VPAC2)[1]
|
|---|---|
| ln Vitro |
As PACAP(1-27), human, ovine, rat, and PACAP(1-38) equipotently displace radioligand binding with a Kd of 1-2 nM, while vasoactive intestinal peptide (VIP) is 1000-fold less potent, radioligand receptor binding assays using I-moniodinated PACAP(1-27), human, ovine, rat, and PACAP(1-38) confirm the presence of PAC -receptors on AR4-2J cells. A different and significantly increased susceptibility to VIP-amino acid alterations is shown by PACAP(1-27), human, ovine, and rat. IP3 and cAMP production in AR4-2J cells can be stimulated by PACAP(1-27), human, ovine, and rat, with good potency and binding affinity[2].
|
| ln Vivo |
In anesthetized, ventilated guinea-pigs, the inhibitory effect of pituitary adenylate cyclase activating polypeptide (PACAP (1-27), human, ovine, rat) on the rise in total lung resistance (RL) caused either by allergen or histamine is examined. Inhaled ovalbumin and histamine elicit an increase in RL, which is dose-dependently reduced by PACAP (1-27), human, ovine, and rat administered via intravenous infusion (0.045-4.5 nmol/kg/min). At the maximum dosage, PACAP (1-27), human, ovine, and rat, totally inhibits the ovalbumin and histamine-induced rise in RL. The increase in RL is inhibited similarly by infusions of PACAP (1-27), human, ovine, and rat, and the β2-adrenoceptor agonist ventolin (0.045-4.5 nmol/kg/min); however, salbutamol causes a greater increase in heart rate than PACAP (1-27), human, ovine, and rat[3].
|
| References |
|
| Molecular Formula |
C144H225F3N40O41S
|
|---|---|
| Molecular Weight |
3261.68
|
| Related CAS # |
PACAP (1-27), human, ovine, rat;127317-03-7
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~250 mg/mL (~76.65 mM)
H2O :~12.5 mg/mL (~3.83 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (0.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (0.64 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (0.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3066 mL | 1.5330 mL | 3.0659 mL | |
| 5 mM | 0.0613 mL | 0.3066 mL | 0.6132 mL | |
| 10 mM | 0.0307 mL | 0.1533 mL | 0.3066 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
